Advancing CNS Drug Discovery with Translational EEG Biomarkers
The white paper was specifically made to introduce the subject of in vivo preclinical electroencephalography (EEG) in Central Nervous System (CNS) diseases drug discovery. In this article will be found general information about the EEG technology and its wide potential. Going through all the steps that SynapCell has established to define a translational biomarker, directly inspired from the clinical stage of drug development, the article underlines a mastered biomarker capable of assessing a drug efficacy on a specific and drug-resistant form of focal epilepsy.
Finally, it cover how Synapcell’s Cue® platform is able to phenotype any animal model for CNS disease, by detecting subtle oscillatory changes in the brain activity, empowered by deep-learning-based signal processing.
Figure 1: The Cue® platform provides a versatile tool for drug discovery, accepting EEG input and supporting a wide range of applications.
"The Cue® in vivo platform encompasses high-level modeling methods, precise recording techniques, and deep-learning based signal processing to enable quantification of brain activity in healthy and pathological conditions."